Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Duchenne Muscular Dystrophy Pipeline Drugs Market Report Overview

Duchenne Muscular Dystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects.

Key Targets in the Duchenne Muscular Dystrophy Pipeline Market

The key targets in the Duchenne Muscular Dystrophy pipeline market are Dystrophin, Utrophin, Androgen Receptor, Glucocorticoid Receptor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Connective Tissue Growth Factor, and Growth/Differentiation Factor 8. Dystrophin has the highest pipeline products.

Duchenne Muscular Dystrophy Pipeline Market, by Targets

Duchenne Muscular Dystrophy Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Duchenne Muscular Dystrophy Pipeline Market

The key MoA in the Duchenne Muscular Dystrophy pipeline market are Dystrophin Activator, Utrophin Activator, Glucocorticoid Receptor Agonist, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Androgen Receptor Agonist, Connective Tissue Growth Factor Inhibitor, and Growth/Differentiation Factor 8 Inhibitor. Dystrophin Activator has the highest pipeline products.

Duchenne Muscular Dystrophy Pipeline Market, by MoA

Duchenne Muscular Dystrophy Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Duchenne Muscular Dystrophy Pipeline Market

The key RoA in the Duchenne Muscular Dystrophy pipeline market are oral, intravenous, subcutaneous, parenteral, inhalational, intramuscular, intracoronary, intrathecal, intravascular, ophthalmic, and topical. Oral has the highest number of pipeline products.

Duchenne Muscular Dystrophy Pipeline Market, by RoA

Duchenne Muscular Dystrophy Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Type in the Duchenne Muscular Dystrophy Pipeline Market

The key molecule type in the Duchenne Muscular Dystrophy pipeline market are small molecule, antisense oligonucleotide, gene therapy, cell therapy, oligonucleotide, monoclonal antibody conjugated, recombinant protein, synthetic peptide, fusion protein, gene-modified cell therapy, monoclonal antibody, protein, antisense RNAI oligonucleotide, and biologic. Small molecule has the highest pipeline products.

Duchenne Muscular Dystrophy Pipeline Market, by Molecule Types

Duchenne Muscular Dystrophy Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Duchenne Muscular Dystrophy Pipeline Market

The key companies in the Duchenne Muscular Dystrophy pipeline market are Sarepta Therapeutics Inc, Daiichi Sankyo Co Ltd, Dystrogen Therapeutics SA, NS Pharma Inc, Avidity Biosciences Inc, Nippon Shinyaku Co Ltd, Pepgen Ltd, and Sarcomed AB. Sarepta Therapeutics Inc has the highest number of pipeline products. 

Avidity Biosciences Inc: Avidity Biosciences Inc (Avidity Biosciences), formerly Avidity NanoMedicines LLC is a biotech company that develops antibody oligonucleotide conjugates (AOCs). Its proprietary platform technology has enhanced pharmacokinetic and biodistribution properties that improve the delivery of multiple therapeutic oligonucleotides. Its pipeline of therapeutic programs is intended for the treatment of rare muscle disorders and other serious diseases, including Duchenne muscular dystrophy, myotonic dystrophy, and muscle atrophy. The company has research collaborations with leading pharma companies, to discover antibody-based drug candidates against various therapeutic targets. Avidity Biosciences is headquartered in San Diego, California, the US. 

Duchenne Muscular Dystrophy Pipeline Market, by Companies

Duchenne Muscular Dystrophy Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Dystrophin, Utrophin, Androgen Receptor, Glucocorticoid Receptor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Connective Tissue Growth Factor, and Growth/Differentiation Factor 8
Key MoA Dystrophin Activator, Utrophin Activator, Glucocorticoid Receptor Agonist, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Androgen Receptor Agonist, Connective Tissue Growth Factor Inhibitor, and Growth/Differentiation Factor 8 Inhibitor
Key RoA Oral, Intravenous, Subcutaneous, Parenteral, Inhalational, Intramuscular, Intracoronary, Intrathecal, Intravascular, Ophthalmic, and Topical
Key molecule types Small Molecule, Antisense Oligonucleotide, Gene Therapy, Cell Therapy, Oligonucleotide, Monoclonal Antibody Conjugated, Recombinant Protein, Synthetic Peptide, Fusion Protein, Gene-Modified Cell Therapy, Monoclonal Antibody, Protein, Antisense RNAI Oligonucleotide, and Biologic
Key companies Sarepta Therapeutics Inc, Daiichi Sankyo Co Ltd, Dystrogen Therapeutics SA, NS Pharma Inc, Avidity Biosciences Inc, Nippon Shinyaku Co Ltd, Pepgen Ltd, and Sarcomed AB

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

AAVogen Inc
Alpha Anomeric
American CryoStem Corp
Anagenesis Biotechnologies SAS
Antisense Therapeutics Ltd
ARMGO Pharma Inc
Astria Therapeutics Inc
AUM LifeTech Inc
Autotac Bio Inc
Avidity Biosciences Inc
Axolo Pharma Inc
Bayer AG
Biogen Inc
BioIncept LLC
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SA
CANbridge Life Sciences Ltd
Capricor Therapeutics Inc
Chengdu Fanxi Biopharma Co Ltd
Code Biotherapeutics Inc
Consortium.AI
Constant Therapeutics LLC
CRISPR Therapeutics AG
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
DepYmed Inc
DMD Therapeutics Inc
DTx Pharma Inc
Dyne Therapeutics Inc
Dystrogen Therapeutics SA
Edgewise Therapeutics Inc
Editas Medicine Inc
Eli Lilly and Co
Eloxx Pharmaceuticals Inc
Encell Co Ltd
Entrada Therapeutics Inc
Epirium Bio Inc
EryDel SpA
Evox Therapeutics Ltd
FibroGen Inc
FibroGenesis LLC
Fulcrum Therapeutics Inc
InnoBioscience LLC
Italfarmaco SpA
Ixchel Pharma LLC
J2H Biotech
Keros Therapeutics Inc
KSbitugen Co Ltd
LambdaGen Therapeutics
Ludi Therapeutics
Milo Biotechnology LLC
Mitobridge Inc
Mitochon Pharmaceuticals Inc
MitoRx Therapeutics Ltd
MyoGene Bio LLC
Myos Inc
Myosana Therapeutics Inc
MyoTherix Inc
Nippon Shinyaku Co Ltd
NS Pharma Inc
OliPass Corporation
OMEICOS Therapeutics GmbH
Oncocross Co Ltd
Oncotelic Inc
Pepgen Ltd
PeptiDream Inc
Pfizer Inc
Pharmaxis Ltd
PhaseBio Pharmaceuticals Inc
Pliant Therapeutics Inc
Progenitor Therapeutics Ltd
Prothelia Inc
PTC Therapeutics Inc
PYC Therapeutics Ltd
RASRx LLC
RegenxBio Inc
ReoStem LLC
Ridgeline Therapeutics LLC
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Sarepta Therapeutics Inc
Satellos Bioscience Inc
Solid Biosciences Inc
Stealth BioTherapeutics Corp
SteroTherapeutics LLC
Sutura Therapeutics Ltd
Suzhou GenAssist Therapeutics Co Ltd
Taiho Pharmaceutical Co Ltd
Tivorsan Pharmaceuticals Inc
Tolerion Inc
Triplex Therapeutics Inc
UGISense AG
Ultragenyx Pharmaceutical Inc
Vandria SA
Vertex Pharmaceuticals Inc
Vita Therapeutics Inc
Wave Life Sciences Ltd
Zata Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Duchenne Muscular Dystrophy – Overview

Duchenne Muscular Dystrophy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Duchenne Muscular Dystrophy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Duchenne Muscular Dystrophy – Companies Involved in Therapeutics Development

Duchenne Muscular Dystrophy – Drug Profiles

Duchenne Muscular Dystrophy – Dormant Projects

Duchenne Muscular Dystrophy – Discontinued Products

Duchenne Muscular Dystrophy – Product Development Milestones

Featured News & Press Releases

Apr 28, 2022: Pfizer to open first U.S. sites in phase 3 trial of investigational gene therapy for ambulatory patients with Duchenne muscular dystrophy

Apr 07, 2022: Dystrogen Therapeutics investigational chimeric cell therapy DT-DEC01 for the treatment of Duchene Muscular Dystrophy shows safety and functional improvements

Apr 06, 2022: PepGen announces first participant dosed in a phase 1 clinical trial of PGN-EDO51 for the treatment of Duchenne Muscular Dystrophy

Mar 29, 2022: Santhera and ReveraGen start rolling NDA submission to the FDA for Vamorolone for the treatment of Duchenne Muscular Dystrophy

Mar 18, 2022: Exon 44-targeted DMD drug hits goals in PI/II: NCNP/Nippon Shinyaku

Mar 17, 2022: The result of an investigator-initiated clinical trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy

Mar 16, 2022: Stealth BioTherapeutics showcases new Duchenne muscular dystrophy nonclinical data at the 2022 Muscular Dystrophy Association and Clinical Scientific Conference

Mar 15, 2022: PepGen announces approval by Health Canada of CTA to begin first in human trials of PGN-EDO51 to treat Duchenne Muscular Dystrophy

Mar 15, 2022: Santhera and ReveraGen to present efficacy and safety data with vamorolone at 2022 Muscular Dystrophy Association Conference

Mar 14, 2022: Significant modulation of two bone morphogenetic proteins supports potential of ATL1102 for improving bone density in DMD

Mar 11, 2022: The Lancet publishes positive results from Capricor Therapeutics’ phase 2 study evaluating CAP-1002 in late-stage Duchenne muscular dystrophy

Mar 11, 2022: The result of an investigator-initiated clinical trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy

Mar 09, 2022: Antisense Therapeutics to present poster at world’s largest NMD conference

Mar 08, 2022: Edgewise Therapeutics to present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference

Mar 08, 2022: Roche to present new SRP-9001 data at MDA 2022 and highlight expanding neuromuscular disease portfolio

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Duchenne Muscular Dystrophy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Duchenne Muscular Dystrophy – Pipeline by AAVogen Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Alpha Anomeric, 2022

Duchenne Muscular Dystrophy – Pipeline by American CryoStem Corp, 2022

Duchenne Muscular Dystrophy – Pipeline by Anagenesis Biotechnologies SAS, 2022

Duchenne Muscular Dystrophy – Pipeline by Antisense Therapeutics Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by ARMGO Pharma Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Astria Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by AUM LifeTech Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Autotac Bio Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Avidity Biosciences Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Axolo Pharma Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Bayer AG, 2022

Duchenne Muscular Dystrophy – Pipeline by Biogen Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by BioIncept LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by Bioleaders Corp, 2022

Duchenne Muscular Dystrophy – Pipeline by BioMarin Pharmaceutical Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Biophytis SA, 2022

Duchenne Muscular Dystrophy – Pipeline by CANbridge Life Sciences Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by Capricor Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by Code Biotherapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Consortium.AI, 2022

Duchenne Muscular Dystrophy – Pipeline by Constant Therapeutics LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by CRISPR Therapeutics AG, 2022

Duchenne Muscular Dystrophy – Pipeline by Cumberland Pharmaceuticals Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Daiichi Sankyo Co Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by DepYmed Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by DMD Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by DTx Pharma Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Dyne Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Dystrogen Therapeutics SA, 2022

Duchenne Muscular Dystrophy – Pipeline by Edgewise Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Editas Medicine Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Eli Lilly and Co, 2022

Duchenne Muscular Dystrophy – Pipeline by Eloxx Pharmaceuticals Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Encell Co Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by Entrada Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Epirium Bio Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by EryDel SpA, 2022

Duchenne Muscular Dystrophy – Pipeline by Evox Therapeutics Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by FibroGen Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by FibroGenesis LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by Fulcrum Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by InnoBioscience LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by Italfarmaco SpA, 2022

Duchenne Muscular Dystrophy – Pipeline by Ixchel Pharma LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by J2H Biotech, 2022

Duchenne Muscular Dystrophy – Pipeline by Keros Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by KSbitugen Co Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by LambdaGen Therapeutics, 2022

Duchenne Muscular Dystrophy – Pipeline by Ludi Therapeutics, 2022

Duchenne Muscular Dystrophy – Pipeline by Milo Biotechnology LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by Mitobridge Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Mitochon Pharmaceuticals Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by MitoRx Therapeutics Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by MyoGene Bio LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by Myos Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Myosana Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by MyoTherix Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Nippon Shinyaku Co Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by NS Pharma Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by OliPass Corporation, 2022

Duchenne Muscular Dystrophy – Pipeline by OMEICOS Therapeutics GmbH, 2022

Duchenne Muscular Dystrophy – Pipeline by Oncocross Co Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by Oncotelic Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Pepgen Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by PeptiDream Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Pfizer Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Pharmaxis Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by PhaseBio Pharmaceuticals Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Pliant Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Progenitor Therapeutics Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by Prothelia Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by PTC Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by PYC Therapeutics Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by RASRx LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by RegenxBio Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by ReoStem LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by Ridgeline Therapeutics LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by Santhera Pharmaceuticals Holding AG, 2022

Duchenne Muscular Dystrophy – Pipeline by Sarcomed AB, 2022

Duchenne Muscular Dystrophy – Pipeline by Sarepta Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Satellos Bioscience Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Solid Biosciences Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Stealth BioTherapeutics Corp, 2022

Duchenne Muscular Dystrophy – Pipeline by SteroTherapeutics LLC, 2022

Duchenne Muscular Dystrophy – Pipeline by Sutura Therapeutics Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by Suzhou GenAssist Therapeutics Co Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by Taiho Pharmaceutical Co Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by Tivorsan Pharmaceuticals Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Tolerion Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Triplex Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by UGISense AG, 2022

Duchenne Muscular Dystrophy – Pipeline by Ultragenyx Pharmaceutical Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Vandria SA, 2022

Duchenne Muscular Dystrophy – Pipeline by Vertex Pharmaceuticals Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Vita Therapeutics Inc, 2022

Duchenne Muscular Dystrophy – Pipeline by Wave Life Sciences Ltd, 2022

Duchenne Muscular Dystrophy – Pipeline by Zata Pharmaceuticals Inc, 2022

Duchenne Muscular Dystrophy – Dormant Projects, 2022

Duchenne Muscular Dystrophy – Discontinued Products, 2022

Duchenne Muscular Dystrophy – Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Duchenne Muscular Dystrophy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.